Versant Venture Capital Vi, L.P. is of Black Diamond Therapeutics, Inc.. Currently has a direct ownership of 3.73 Million shares of BDTX, which is worth approximately $9.28 Million. The most recent transaction as insider was on Oct 08, 2020, when has been sold 16,276 shares (Common Stock) at a price of $33.47 per share, resulting in proceeds of $544,758. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.73M
5.61% 3M change
5.61% 12M change
Total Value Held $9.28 Million

Versant Venture Capital VI, L.P. Transaction History

Date Transaction Value Shares Traded Shares Held Form
Oct 08 2020
SELL
Open market or private sale
$544,758 $33.47 p/Share
16,276 Reduced 0.28%
5,740,384 Common Stock
Oct 07 2020
SELL
Open market or private sale
$825,240 $33.56 p/Share
24,590 Reduced 0.43%
5,756,660 Common Stock
Oct 06 2020
SELL
Open market or private sale
$531,495 $33.26 p/Share
15,980 Reduced 0.28%
5,781,250 Common Stock

Also insider at

ALGS
Aligos Therapeutics, Inc. Healthcare
OYST
Oyster Point Pharma, Inc. Healthcare
IPSC
Century Therapeutics, Inc. Healthcare
GLUE
Monte Rosa Therapeutics, Inc. Healthcare
GRPH
Graphite Bio, Inc. Healthcare
CTNM
Contineum Therapeutics, Inc.
TPST
Tempest Therapeutics, Inc. Healthcare
VVC

Versant Venture Capital Vi, L.P.

San Francisco, CA

Track Institutional and Insider Activities on BDTX

Follow Black Diamond Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BDTX shares.

Notify only if

Insider Trading

Get notified when an Black Diamond Therapeutics, Inc. insider buys or sells BDTX shares.

Notify only if

News

Receive news related to Black Diamond Therapeutics, Inc.

Track Activities on BDTX